$CRVO

BOGER JOSHUA S purchased $3.0M of CRVO (indirect holdings)

BOGER JOSHUA S purchased 955,414 indirectly-held shares of CervoMed Inc. (CRVO) at $3.14 ($3.00M total) on 2026-06-11.

Original reporting
SEC EDGAR · BOGER JOSHUA S
Published Jun 15, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRVO
Neutral
medium confidence
Mentioned
$CRVO
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRVONeutralLow
01

Why it matters

A director and 10% owner purchased $3.0M of shares at $3.14/share (indirect holdings), with no pre-arranged 10b5-1 plan stated.

02

Market read

Traders may treat the insider buy as a mild sentiment input, but the filing alone is unlikely to drive a sustained repricing without additional company catalysts.

03

What to watch

The filing does not disclose any accompanying operational or clinical catalyst; without follow-on company news, traders may overreact to the insider signal.

Relevance 7/10Novelty 5/10Timing: filed 2026-06-15, transaction dated 2026-06-11

Background

The article is an SEC Form 4 insider transaction disclosure for CervoMed Inc. (CRVO).

Company-level read

Ticker impact

$CRVONeutralMedium confidence
Context

CervoMed director and 10% owner BOGER JOSHUA S bought 955,414 shares in an open-market transaction worth about $3.0M.

Expected impact

Likely limited near-term price impact; any effect would be sentiment-driven and modest.

Evidence & confidence

Form 4 provides a fresh, primary-source transaction, but insider buys without accompanying company-specific catalysts typically do not reset valuation expectations.

Market effects

No sector-wide implications disclosed; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The buy is indirect and not under a 10b5-1 plan, so it may reflect personal liquidity or estate structuring rather than a strong forward view.

Key entities

  • CervoMed Inc.

    Subject of the Form 4 insider transaction disclosure.

  • BOGER JOSHUA S

    Director and 10% owner who reported the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRVOMedAI 8/10

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

CervoMed Inc. (CRVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA

$CRVOMedAI 8/10

CervoMed Presents Initial Phase 2a Results Of Neflamapimod In NfvPPA; Data Accepted For ISFTD 2026

CervoMed (CRVO) reported initial Phase 2a trial results for Neflamapimod in nfvPPA, accepted for ISFTD 2026. Early data showed changes in neurodegeneration markers. The trial involves 25 participants across U.S. and U.K. centers. Neflamapimod targets neuroinflammation and has Orphan Drug Designation for frontotemporal dementia. CRVO stock is currently at $2.50, down 0.40%.

$CRVOMedAI 8/10

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT

CervoMed Inc. (CRVO) announced that initial results from its Phase 2a trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA) will be presented at the ISFTD Annual Meeting. The trial, involving 25 participants, aims to evaluate the safety and efficacy of neflamapimod, a drug targeting neuroinflammation and synaptic dysfunction. NfvPPA, a type of frontotemporal dementia, currently has no approved treatments in the U.S. or E.U.

$CRVOMedAI 8/10

CervoMed's neflamapimod wins UK ILAP Innovation Passport for DLB

CervoMed Inc. (CRVO) announced that its drug candidate, neflamapimod, received an Innovation Passport from the UK's ILAP for treating Dementia with Lewy Bodies (DLB). This designation accelerates regulatory review and market access in the UK, validating the drug's potential. The company is seeking a partner for Phase 3 trials and expects interim data from other trials in late 2026.

$CRVOMed

CervoMed Inc. (CRVO): Results of Operations and Financial Condition

CervoMed Inc. (CRVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation und